Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIG-001
- Development stage
- Preclinical
- Lead developer
- Fig Therapeutics
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
FIG-001 is a preclinical-stage multimodal intratumoral gene therapy being developed by Fig Therapeutics for the treatment of prostate cancer. The therapy utilizes the company's proprietary Symphony platform, which employs a high-capacity, helper-dependent adenovirus (HD-Ad) viral vector. FIG-001 is designed to deliver multiple therapeutic payloads directly into the tumor microenvironment, with expression regulated by a tumor-specific promoter to ensure localized activity and minimize systemic toxicity. It is currently being investigated for metastatic castration-resistant prostate cancer (mCRPC) and as a neoadjuvant treatment for high-risk localized prostate cancer.
Beyond the preview
Go deeper on FIG-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIG-001.